Pfizer confirms strong 2026 guidance with growth in oncology and obesity, offering value at 6.4% dividend yield.

Pfizer remains a strong buy due to its undervalued stock, robust drug pipeline, and aggressive growth in oncology and obesity treatments. The company reaffirmed its 2026 revenue guidance of $59.5–$62.5 billion and EPS of $2.8–$3 despite patent expirations. Key strategies include onshoring high-margin production and aggressive cost-cutting to mitigate risks from patent losses and improve operating margins through 2027. With a price-to-earnings ratio of 8.13 and a 6.4% dividend yield, Pfizer offers compelling value compared to peers, though risks remain around patent cliffs and execution of its obesity platform.